Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2643–2652. doi: 10.1161/ATVBAHA.111.233189

Figure 1.

Figure 1

Reduction of IQ domain GTPase-activating protein 1 (IQGAP1) is sufficient to disrupt basal endothelial barrier function. A, Immunoblot for IQGAP1 72 hours after control or IQGAP1 small interfering RNA (siRNA) transfection in human microvascular endothelial cells (HMVECs). B, Immunocytochemistry 72 hours after control or IQGAP1 siRNA transfection in HMVECs. White arrow (merged inset) highlights severe gap formation between adjacent ECs (representative of 4 independent experiments) (scale bars=10 μm). DAPI indicates 4,6-diamidino-2-phenylindole. C, Bar graph ± SEM showing the Δ between normalized transendothelial electrical resistance (TER) in IQGAP1-silenced and control silenced HMVECs at multiple time points after siRNA transfection (n=4 per condition). TER normalization refers to the start point of the experiment for each condition (ie, 32 hours after siRNA transfection, when cells reached 100% confluence).